Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: Delapril HCL
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

83435-67-0

83435-67-0 structure

83435-67-0 structure

Name: delapril hcl
Chemical Name: Delapril Hydrochloride
CAS Number: 83435-67-0
Molecular Formula: C₂₆H₃₃ClN₂O₅
Molecular Weight: 489.004
Catalog: API Circulatory system medication Antihypertensive drug
Create Date: 2018-07-05 10:13:32
Modify Date: 2026-07-01 14:57:42
Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].

Name	Delapril Hydrochloride
Synonyms	Alindapril Hydrochloride Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycbonyl)-3-phenylpropyl]-L-alanyl]-, monohydrochloride, (S) DELAPRIL HCL N-[(S)-1-Ethoxycbonyl-3-phenylpropyl]-L-alanyl-N-(2,3-dihydroinden-2-yl)glycine Hydrochloride delapril hydrochloride ACE,cdiovascul,Delapril,inhibit,diseases,Inhibitor,Angiotensin-converting Enzyme (ACE),Delapril hydrochloride DELAPRIL HCL //BP Cupressin Defolder 2-((S)-N-(2,3-Dihydro-1H-inden-2-yl)-2-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanamido)acetic acid hydrochloride DelaprilHydrochloride> Dalapril Hcl N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)glycine hydrochloride (1:1) REV 6000A N-(N-((S)-1-Ethoxycbonyl-3-phenylpropyl)-L-alanyl)-N-(indan-2-yl)gly cine hydrochloride Glycine, N-[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)-, monohydrochloride MFCD00884619 Adecut Delapril hydrochloride, 10 mM in DMSO N-[(2S)-1-Ethoxy-1-oxo-4-phenyl-2-butanyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)glycine hydrochloride (1:1) Glycine, N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)-, hydrochloride (1:1) Glycine,N-[(1S)-1-(ethoxycbonyl)-3-phenylpropyl]-L-alanyl-N-(2,3-dihydro-1H-inden-2-yl)-,hydrochloride (1:1) N-(2,3-Dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycbonyl)-3-phenylpropyl]-L-alanyl]glycine monohydrochloride

Description	Delapril is an angiotensin-converting enzyme (ACE) inhibitor for the treatment of cardiovascular diseases[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Angiotensin-converting Enzyme (ACE)
Target	ACE[1]
In Vivo	Delapril (3 mg/kg; administered orally for 2 weeks) exerts potent ACE inhibitory activity in spontaneously hypertensive rat (SHR) [1]. Delapril (1-10 mg/kg; orally) exerts a marked and long-lasting antihypertensive action in various experimental models of hypertension[1]. Animal Model: SHR[1] Dosage: 3 mg/kg Administration: Administered orally; 2 weeks Result: Exerted potent ACE inhibitory activity. Animal Model: 2-kidney, 1-clip hypertensive Rats, Dogs, and SHR[1] Dosage: 1-10 mg/kg Administration: Oral Result: Exerted a marked and long-lasting antihypertensive action.
References	[1]. Razzetti R, et al. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am J Cardiol. 1995 Jun 16;75(18):7F-12F.

Boiling Point	659.7ºC at 760 mmHg
Melting Point	169ºC
Molecular Formula	C₂₆H₃₃ClN₂O₅
Molecular Weight	489.004
Flash Point	352.7ºC
Exact Mass	488.207794
PSA	95.94000
LogP	3.80250

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MB9668000

CHEMICAL NAME :: Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-(N-(1-(ethoxycarbonyl )-3-phenylpropyl)-L-a lanyl)-, monohydrochloride, (S)-

CAS REGISTRY NUMBER :: 83435-67-0

LAST UPDATED :: 199206

DATA ITEMS CITED :: 8

MOLECULAR FORMULA :: C26-H32-N2-O5.Cl-H

MOLECULAR WEIGHT :: 489.06

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 8260 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 208 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5900 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3120 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 164 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 2340 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea Nutritional and Gross Metabolic - body temperature decrease

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 27300 mg/kg/13W-C

TOXIC EFFECTS :: Blood - changes in leukocyte (WBC) count

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),31,1987 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 8700 mg/kg

SEX/DURATION :: female 15-22 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 15(Suppl 1),203,1987

83435-61-4 structure

83435-61-4

~92%

83435-67-0 structure

83435-67-0

Literature: Takeda Chemical Industries, Ltd. Patent: US4835302 A1, 1989 ;

1001015-87-7 structure

1001015-87-7

84793-24-8 structure

84793-24-8

~91%

83435-67-0 structure

83435-67-0

Literature: DIPHARMA FRANCIS s.r.l. Patent: US2008/15383 A1, 2008 ; Location in patent: Page/Page column 3 ;

83435-62-5 structure

83435-62-5

~71%

83435-67-0 structure

83435-67-0

Literature: Miyake; Itoh; Oka Chemical and Pharmaceutical Bulletin, 1986 , vol. 34, # 7 p. 2852 - 2858

64920-29-2 structure

64920-29-2

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

83402-63-5 structure

83402-63-5

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

80828-38-2 structure

80828-38-2

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

80828-26-8 structure

80828-26-8

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

615-13-4 structure

615-13-4

~%

83435-67-0 structure

83435-67-0

Literature: Chemical and Pharmaceutical Bulletin, , vol. 34, # 7 p. 2852 - 2858

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.